Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?

References

• Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777–89. doi:10.1016/S0140-6736(00)04904-7.
   PubMed Web of Science ®Google Scholar
• Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57:552–56. doi:10.1093/occmed/kqm110.
   PubMed Web of Science ®Google Scholar
• Heffernan JM, Keeling MJ. Implications of vaccination and waning immunity. Proc Biol Sci. 2009;276:2071–80. doi:10.1098/rspb.2009.0057.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–52. doi:10.1038/s41591-020-0820-9.
   PubMed Web of Science ®Google Scholar
• Yee S, Tan CS, Khan A, Lee KS, Goh BH, Ming LC. SARS-COV-2 as an artificial creation: scientific arguments and counterarguments. J Med Life. 2021;14:118–20. doi:10.25122/jml-2020-0175.
   PubMedGoogle Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583–89. doi:10.1016/j.immuni.2020.03.007.
   PubMed Web of Science ®Google Scholar
• Thakur S, Sarkar B, Ansari AJ, Khandelwal A, Arya A, Poduri R, Joshi G. Exploring the magic bullets to identify Achilles’ heel in SARS-CoV-2: delving deeper into the sea of possible therapeutic options in Covid-19 disease: an update. Food Chem Toxicol. 2021;147:111887. doi:10.1016/j.fct.2020.111887.
   PubMed Web of Science ®Google Scholar
• Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. Cell Signal. 2020;74:109721. doi:10.1016/j.cellsig.2020.109721.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011;9:889–93. doi:10.1038/nrmicro2668.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA. 2014;111:12288–93. doi:10.1073/pnas.1402981111.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Jaffee EM, Warren N, D’Souza G, Ribas A. How did we get a COVID-19 vaccine in less than 1 year?. Clin Cancer Res. 2021;27:2136–38. doi:10.1158/1078-0432.CCR-21-0079.
   PubMed Web of Science ®Google Scholar
• Funk CD, Laferriere C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020;11:937. doi:10.3389/fphar.2020.00937.
   PubMed Web of Science ®Google Scholar
• Zepp F. Principles of vaccine design—lessons from nature. Vaccine. 2010;28:C14–C24. doi:10.1016/j.vaccine.2010.07.020.
   PubMed Web of Science ®Google Scholar
• Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform. 2015;53:405–14. doi:10.1016/j.jbi.2014.11.003.
   PubMed Web of Science ®Google Scholar
• Rueckert C, Guzman CA. Vaccines: from empirical development to rational design. PLoS Pathog. 2012;8:e1003001. doi:10.1371/journal.ppat.1003001.
   PubMed Web of Science ®Google Scholar
• Abidi A, Can M. On the accuracies of sequence based linear B cell epitope predictors. Southeast Eur J Soft Comput. 2018;6. doi:10.21533/scjournal.v6i2.142.
   Google Scholar
• Wang J, Wang H, Wang X, Chang H. Predicting drug-target interactions via FM-DNN learning. Curr Bioinform. 2020;15:68–76. doi:10.2174/1574893614666190227160538.
   Web of Science ®Google Scholar
• Wong KK. Optimization in the design of natural structures, biomaterials, bioinformatics and biometric techniques for solving physiological needs and ultimate performance of bio-devices. Curr Bioinform. 2019;14:374–75. doi:10.2174/157489361405190628122355.
   Web of Science ®Google Scholar
• Fast E, Altman RB, Chen B. Potential T-cell and B-cell epitopes of 2019-nCoV. BioRxiv 2020:2020 02 19 955484. doi:10.1101/2020.02.19.955484.
   Google Scholar
• Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol. 2020;11:1581. doi:10.3389/fimmu.2020.01581.
   PubMed Web of Science ®Google Scholar
• Yang Z, Bogdan P, Nazarian S. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. Sci Rep. 2021;11:3238. doi:10.1038/s41598-021-81749-9.
   PubMed Web of Science ®Google Scholar
• Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019;47:D339–D43. doi:10.1093/nar/gky1006.
   PubMed Web of Science ®Google Scholar
• Toussaint NC, Kohlbacher O. OptiTope—a web server for the selection of an optimal set of peptides for epitope-based vaccines. Nucleic Acids Res. 2009;37:W617–W22. doi:10.1093/nar/gkp293.
   PubMed Web of Science ®Google Scholar
• Karosiene E, Lundegaard C, Lund O, Nielsen M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics. 2012;64:177–86. doi:10.1007/s00251-011-0579-8.
   PubMed Web of Science ®Google Scholar
• Sharma R, Palanisamy A, Dhama K, Mal G, Singh B, Singh KP. Exploring the possible use of saponin adjuvants in COVID-19 vaccine. Hum Vaccines Immunother. 2020;16:2944–53. doi:10.1080/21645515.2020.1833579.
   PubMed Web of Science ®Google Scholar
• Cox JC, Coulter AR. Adjuvants—a classification and review of their modes of action. Vaccine. 1997;15:248–56. doi:10.1016/s0264-410x(96)00183-1.
   PubMed Web of Science ®Google Scholar
• Pulendran B, S. Arunachalam P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20:454–75. doi:10.1038/s41573-021-00163-y.
   PubMed Web of Science ®Google Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114. doi:10.3389/fimmu.2013.00114.
   PubMed Web of Science ®Google Scholar
• McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol. 2010;8:1–10. doi:10.1186/1741-7007-8-37.
   PubMed Web of Science ®Google Scholar
• Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594. doi:10.3389/fimmu.2019.00594.
   PubMed Web of Science ®Google Scholar
• Federico S, Pozzetti L, Papa A, Carullo G, Gemma S, Butini S, Campiani G, Relitti N. Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists. J Med Chem. 2020;63:13466–513. doi:10.1021/acs.jmedchem.0c01049.
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8:360–76. doi:10.1002/cmdc.201200487.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12:509–17. doi:10.1038/ni.2039.
   PubMed Web of Science ®Google Scholar
• Gomez PL, Robinson JM. Vaccine manufacturing. Plotkin’s Vaccines. 2018;51–60.e1. doi:10.1016/B978-0-323-35761-6.00005-5.
   Google Scholar
• Philippidis A. COVID-19: top 60 drug treatments in development: the biopharma industry is ramping up the development of dozens of potential drug therapies and clinical testing in an all-hands effort to combat the pandemic. Genet Eng Biotechnol News. 2020;40:10–13. doi:10.1089/gen.40.04.02.
   Google Scholar
• Rodrigues CM, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020;11. doi:10.3389/fmicb.2020.01526.
   Web of Science ®Google Scholar
• Saylor K, Gillam F, Lohneis T, Zhang C. Designs of antigen structure and composition for improved protein-based vaccine efficacy. Front Immunol. 2020;11:283. doi:10.3389/fimmu.2020.00283.
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6:104. doi:10.1038/s41541-021-00369-6.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:83–100. doi:10.1038/s41577-020-00479-7.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27. doi:10.1038/s41586-020-2798-3.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–68. doi:10.1126/science.1690918.
   PubMed Web of Science ®Google Scholar
• Borah P, Deb PK, Deka S, Venugopala KN, Singh V, Mailavaram RP, Kalia K, Tekade RK. Current scenario and future prospect in the management of COVID-19. Curr Med Chem. 2021;28:284–307. doi:10.2174/0929867327666200908113642.
   PubMed Web of Science ®Google Scholar
• Borah P, Deb PK, Al-Shar’i NA, Dahabiyeh LA, Venugopala KN, Singh V, Shinu P, Hussain S, Deka S, Chandrasekaran B. Perspectives on RNA vaccine candidates for COVID-19. Front Mol Biosci. 2021;8:635245. doi:10.3389/fmolb.2021.635245.
   PubMed Web of Science ®Google Scholar
• Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). 2019;7:37. doi:10.3390/vaccines7020037.
   PubMed Web of Science ®Google Scholar
• Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012;86:2900–10. doi:10.1128/JVI.05738-11.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomed. 2019;14:1937. doi:10.2147/IJN.S198353.
   PubMed Web of Science ®Google Scholar
• de Queiroz N, Marinho FV, Chagas MA, Leite LCC, Homan EJ, de Magalhaes MTQ, Oliveira SC. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes Infect. 2020;22:515–24. doi:10.1016/j.micinf.2020.09.004.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Chiarot E, Giovani C, Buccato S, Bonacci S, Frigimelica E, Margarit I, Geall A, Bensi G, Maione D, et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine. 2017;35:361–68. doi:10.1016/j.vaccine.2016.11.040.
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109:14604–09. doi:10.1073/pnas.1209367109.
   PubMed Web of Science ®Google Scholar
• Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, Brill S, Haefner E, Becker R, Türeci Ö, et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther. 2020;28(1):119–28. doi:10.1016/j.ymthe.2019.09.009.
   PubMed Web of Science ®Google Scholar
• Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28:117–29. doi:10.1038/s41434-020-00204-y.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:128. doi:10.1038/s41419-019-1413-8.
   PubMed Web of Science ®Google Scholar
• Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318–24. doi:10.1038/d41586-021-02483-w.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383:1920–31. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110:997–1001. doi:10.1016/j.xphs.2020.12.006.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Medrxiv. 2020. doi:10.1101/2020.08.17.20176651.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495–501. doi:10.1007/s40265-021-01480-7.
   PubMed Web of Science ®Google Scholar
• Mukherjee R. Global efforts on vaccines for COVID-19: since, sooner or later, we all will catch the coronavirus. J Biosci. 2020;45:1–10. doi:10.1007/s12038-020-00040-7.
   PubMed Web of Science ®Google Scholar
• Oostvogels L, Kremsner P, Kreidenweiss A, Leroux-Roels I, Leroux-Roels G, Kroidl A, Schunk M, Schindler C, Bosch J, Fendel R, Gabor JJ. Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. Medrxiv. 2020. doi:10.1101/2020.11.09.20228551.
   Google Scholar
• Silveira MM, Oliveira TL, Schuch RA, McBride AJA, Dellagostin OA, Hartwig DD. DNA vaccines against leptospirosis: a literature review. Vaccine. 2017;35:5559–67. doi:10.1016/j.vaccine.2017.08.067.
   PubMed Web of Science ®Google Scholar
• Duerr GD, Heine A, Hamiko M, Zimmer S, Luetkens JA, Nattermann J, Rieke G, Isaak A, Jehle J, Held SAE, et al. Parameters predicting COVID-19-induced myocardial injury and mortality. Life Sci. 2020;260:118400. doi:10.1016/j.lfs.2020.118400.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–93. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Lee P, Kim CU, Seo SH, Kim DJ. Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages. Immune Network. 2021;21:e4. doi:10.4110/in.2021.21.e4.
   PubMed Web of Science ®Google Scholar
• Coronavirus vaccine tracker. [ accessed 2021 Sep 19]. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
   Google Scholar
• Bottomley MJ, Rappuoli R, Finco O. Vaccine design in the 21st century. In: Bloom BR, and Lambert P-H, editors. The vaccine book. USA: Academic Press; 2016. p. 45–65.
   Google Scholar
• Chen J, Gao K, Wang R, Wei GW. Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chem Sci. 2021;12:6929–48. doi:10.1039/d1sc01203g.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20. doi:10.1038/s41586-020-2180-5.
   PubMed Web of Science ®Google Scholar
• Callaway E, Mallapaty S. Novavax covid vaccine protects people against variants. Nature. 2021;590:17. doi:10.1038/d41586-021-00268-9.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–32. doi:10.1056/NEJMoa2026920.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. Br Med J. 2021. doi:10.1136/bmj.n296.
   Google Scholar
• Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?. Med Drug Discov. 2020;5:100028. doi:10.1016/j.medidd.2020.100028.
   PubMedGoogle Scholar
• Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–94. doi:10.1016/S0140-6736(21)00241-5.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21:73–82. doi:10.1038/s41577-020-00480-0.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885–98. doi:10.1056/NEJMoa2102214.
   PubMed Web of Science ®Google Scholar
• Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol. 2020;18:2835–36. doi:10.1016/j.cgh.2020.07.050.
   PubMed Web of Science ®Google Scholar
• Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug Remdesivir: an update. Biomed Pharmacother. 2020;130:110532. doi:10.1016/j.biopha.2020.110532.
   PubMed Web of Science ®Google Scholar
• Ryzhikov AB, Ryzhikov EА, Bogryantseva MP, Danilenko ED, Imatdinov IR, Nechaeva EA, Pyankov OV, Pyankova OG, Susloparov IM, Taranov OS, Gudymo AS, Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2. Ann Russ Acad Sci Med Sci. 2021;76:5–19. doi:10.15690/vramn1528.
   Google Scholar
• Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Investigators SC, Association between early treatment with Tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern Med. 2021;181:41–51. doi:10.1001/jamainternmed.2020.6252.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kuo L, Peng J, Huang JH, Kuo B, Lin F, A novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an Adeno associated virus human angiotensin-converting enzyme 2 (AAV hACE2) mouse model. BioRxiv. 202010.1101/2020.11.30.399154.
   Google Scholar
• Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol. 2009;157:153–65. doi:10.1038/bjp.2008.349.
   PubMed Web of Science ®Google Scholar
• Bezbaruah R, Borah P, Kakoti BB, Al-Shar IN, Chandrasekaran B, Jaradat DMM, Al-Zeer MA, Abu-Romman S, Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19. Front Mol Biosci. 2021;8:635337. doi:10.3389/fmolb.2021.635337.
   PubMed Web of Science ®Google Scholar
• van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19:810–12. doi:10.1038/s41563-020-0746-0.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Khan Sharun RS, Dhama K. Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low-and middle-income countries. Ann Med Surg. 2021. doi:10.1016/j.amsu.2021.102264.
   Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:72–74. doi:10.1016/S0140-6736(20)32623-4.
   PubMed Web of Science ®Google Scholar
• Xi CE, Singh J. A review of the animal and human trials of the Ad5-nCoV vaccine candidate. Int J Stud Res. 2021;10. doi:10.47611/jsr.v10i1.1159.
   Google Scholar
• Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11:4081. doi:10.1038/s41467-020-17972-1.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Stephenson E, Reynolds G, Botting RA, Calero-Nieto FJ, Morgan MD, Tuong ZK, Bach K, Sungnak W, Worlock KB, Yoshida M, et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nat Med. 2021;27(5):904–16. doi:10.1038/s41591-021-01329-2.
   PubMed Web of Science ®Google Scholar
• Roldão A, Mellado MCM, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9:1149–76. doi:10.1586/erv.10.115.
   PubMed Web of Science ®Google Scholar
• Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, Ahmadian G. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021;19:1–27. doi:10.1186/s12951-021-00806-7.
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A. C, Elouahabi A, Harvengt P, Carlsen H, Kielland A. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29:2461–73. doi:10.1016/j.vaccine.2011.01.011.
   PubMed Web of Science ®Google Scholar
• Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, Janssens M, Leroux-Roels G, Marchant A, van den Berg RA, Garçon N M, Leroux-Roels G, Marchant A, Van den Berg RA, Garçon N. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol. 2017;8:943. doi:10.3389/fimmu.2017.00943.
   PubMed Web of Science ®Google Scholar
• Ward BJ, Gobeil P, Seguin A, Atkins J, Boulay I, Charbonneau PY, Couture M, D’Aoust M-A, Dhaliwall J, Finkle C, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med. 2021;27:1071–78. doi:10.1038/s41591-021-01370-1.
   PubMed Web of Science ®Google Scholar
• Gobeil P, Pillet S, Séguin A, Boulay I, Mahmood A, Vinh DC, Charland N, Boutet P, Roman FP, Van Der Most R, Perez MD N, Boutet P, Roman FP, Van Der Most R, Perez MD. Interim report of a phase 2 randomized trial of a plant-produced virus-like particle vaccine for Covid-19 in healthy adults aged 18-64 and older adults aged 65 and older. Medrxiv. 2021. doi:10.1101/2021.05.14.21257248.
   Google Scholar
• Bakhiet M, Taurin S. SARS-CoV-2: targeted managements and vaccine development. Cytokine Growth Factor Rev. 2021;58:16–29. doi:10.1016/j.cytogfr.2020.11.001.
   PubMed Web of Science ®Google Scholar
• Khuroo MS, Khuroo M, Khuroo MS, Sofi AA, Khuroo NS. COVID-19 vaccines: a race against time in the middle of death and devastation! J Clin Exp Hepatol. 2020;10:610–21. doi:10.1016/j.jceh.2020.06.003.
   PubMed Web of Science ®Google Scholar
• Tielemans S, de Melker HE, Hahne SJM, Boef AGC, van der Klis FRM, Sanders EAM, van der Sande MAB, Knol MJ. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. Br Med J. 2017;358:j3862. doi:10.1136/bmj.j3862.
   PubMed Web of Science ®Google Scholar
• Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014;111:12283–87. doi:10.1073/pnas.1400472111.
   PubMed Web of Science ®Google Scholar
• Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–35. doi:10.1038/s41423-020-0402-2.
   PubMed Web of Science ®Google Scholar
• Netland J, DeDiego ML, Zhao J, Fett C, Alvarez E, Nieto-Torres JL, Enjuanes L, Perlman S. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology. 2010;399:120–28. doi:10.1016/j.virol.2010.01.004.
   PubMed Web of Science ®Google Scholar
• Hou Y, Meulia T, Gao X, Saif LJ, Wang Q, Gallagher T. Deletion of both the tyrosine-based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs. J Virol. 2019;93. doi:10.1128/JVI.01758-18.
   Web of Science ®Google Scholar
• Menachery VD, Yount BL Jr., Josset L, Gralinski LE, Scobey T, Agnihothram S, Katze MG, Baric RS. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2’-o-methyltransferase activity. J Virol. 2014;88:4251–64. doi:10.1128/JVI.03571-13.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, Wu X, Yan Y, Zhao W, Wu J. COVID-19: Coronavirus vaccine development updates. Front Immunol. 2020;11:602256. doi:10.3389/fimmu.2020.602256.
   PubMed Web of Science ®Google Scholar
• Sharun K, Dhama K. India’s role in COVID-19 vaccine diplomacy. J Travel Med. 2021;28. doi:10.1093/jtm/taab064.
   PubMed Web of Science ®Google Scholar
• Luca S, Mihaescu T. History of BCG vaccine. Maedica (Bucur). 2013;8:53–58. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749764/.
   PubMedGoogle Scholar
• Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. [ accessed 2021 Sep 10]. https://www.who.int/immunization/sage/meetings/2017/october/1_BCG_report_revised_version_online.pdf .
   Google Scholar
• Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther. 2013;35:109–14. doi:10.1016/j.clinthera.2013.01.007.
   PubMed Web of Science ®Google Scholar
• Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375–88. doi:10.1038/s41577-020-0285-6.
   PubMed Web of Science ®Google Scholar
• Moorlag S, Arts RJW, Van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25:1473–78. doi:10.1016/j.cmi.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. Medrxiv. 2020. doi:10.1101/2020.03.24.20042937.
   Google Scholar
• Hegarty PK, Kamat A, Zafirakis H, Dinardo A. BCG vaccination may be protective against Covid-19. Preprint. 2020. doi:10.13140/RG.2.2.35948.10880.
   Google Scholar
• Dayal D, Gupta S. Connecting BCG vaccination and COVID-19: additional data. Medrxiv. 2020. doi:10.1101/2020.04.07.20053272.
   Google Scholar
• Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief, 12 April 2020. [accessed 2021 Sep 10]. https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19 .
   Google Scholar
• Fu W, Ho PC, Liu CL, Tzeng KT, Nayeem N, Moore JS, Wang L-S, Chou S-Y. Reconcile the debate over protective effects of BCG vaccine against COVID-19. Sci Rep. 2021;11:8356. doi:10.1038/s41598-021-87731-9.
   PubMed Web of Science ®Google Scholar
• Birkhoff M, Leitz M, Marx D. Advantages of intranasal vaccination and considerations on device selection. Indian J Pharm Sci. 2009;71:729–31. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846493/ .
   Web of Science ®Google Scholar
• Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, Jeannet R, Laterre P-F, Hotchkiss RS, Moldawer LL. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med. 2020;8:946–49. doi:10.1016/S2213-2600(20)30217-4.
   PubMed Web of Science ®Google Scholar
• Greenwood M, Yule GU. The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med. 1915;8:113–94. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2004181/ .
   PubMedGoogle Scholar
• Moore JP. Approaches for optimal use of different COVID-19 vaccines: issues of viral variants and vaccine efficacy. JAMA. 2021;325:1251–52. doi:10.1001/jama.2021.3465.
   PubMed Web of Science ®Google Scholar
• Goldfarb JL, Kreps S, Brownstein JS, Kriner DL. Beyond the first dose - Covid-19 vaccine follow-through and continued protective measures. N Engl J Med. 2021;385:101–03. doi:10.1056/NEJMp2104527.
   PubMed Web of Science ®Google Scholar
• Abbasi J. Study suggests lasting immunity after COVID-19, with a big boost from vaccination. JAMA. 2021;326:376–77. doi:10.1001/jama.2021.11717.
   PubMed Web of Science ®Google Scholar
• Hung IF, Poland GA. Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet. 2021;397:854–55. doi:10.1016/S0140-6736(21)00528-6.
   PubMed Web of Science ®Google Scholar
• Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, Jones J, House T, VanSteenHouse H, Bell I, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021;27:1370–78. doi:10.1038/s41591-021-01410-w.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Polack FP, Zerbini C, Bailey R. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. Medrxiv. 2021. doi:10.1101/2021.07.28.21261159.
   Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, et al. BNT162b2 vaccine booster dose protection: a nationwide study from Israel. N Engl J Med. 2021;385:1393–400. doi:10.1056/NEJMoa2114255.
   PubMed Web of Science ®Google Scholar
• Moore JP, Offit PA. SARS-CoV-2 vaccines and the growing threat of viral variants. JAMA. 2021;325:821–22. doi:10.1001/jama.2021.1114.
   PubMed Web of Science ®Google Scholar
• Martin MA, VanInsberghe D, Koelle K. Insights from SARS-CoV-2 sequences. Science. 2021;371:466–67. doi:10.1126/science.abf3995.
   PubMed Web of Science ®Google Scholar
• Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, De Negri P, Di Gennaro C, Pagano A, Allegorico E, Bressy L. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24:4040–47. doi:10.26355/eurrev_202004_20875.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic. Science. 2021;372(6549):1375–76. doi:10.1126/science.372.6549.1375.
   Web of Science ®Google Scholar
• Delta variant: what we know about the science. [ accessed 2021 Sep 15]. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html .
   Google Scholar
• Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Sanderson K. COVID vaccines protect against Delta, but their effectiveness wanes. Nature. 2021. doi:10.1038/d41586-021-02261-8.
   Google Scholar
• Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2) variant in Qatar. Medrxiv. 2021. doi:10.1101/2021.08.11.21261885.
   Google Scholar
• Novavax announces COVID-19 vaccine booster data demonstrating four-fold increase in neutralizing antibody levels versus peak responses after primary vaccination. [ accessed 2021 Sep 15]. https://ir.novavax.com/2021-08-05-Novavax-Announces-COVID-19-Vaccine-Booster-Data-Demonstrating-Four-Fold-Increase-in-Neutralizing-Antibody-Levels-Versus-Peak-Responses-After-Primary-Vaccination .
   Google Scholar
• Russia’s Sputnik V shot around 83% effective against delta variant, health minister says. [ accessed 2021 Sep 15]. https://www.reuters.com/business/healthcare-pharmaceuticals/russias-sputnik-v-shot-around-83-effective-against-delta-variant-health-minister-2021-08-11/ .
   Google Scholar
• Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira I, Datir R, Collier DA, Albecka A, Singh S, et al. SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. Nature. 2021. doi:10.1038/s41586-021-03944-y.
   Google Scholar
• Rubin R. COVID-19 vaccines vs variants—determining how much immunity is enough. JAMA. 2021;325:1241–43. doi:10.1001/jama.2021.3370.
   PubMed Web of Science ®Google Scholar
• Green MD, Al-Humadi NH. Preclinical toxicology of vaccines. In: A comprehensive guide to toxicology in nonclinical drug development; 2017. p. 709–35. doi:10.1016/B978-0-12-803620-4.00027-X.
   Google Scholar
• Hernandez AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep. 2021;8:871–79. doi:10.1016/j.toxrep.2021.04.003.
   PubMedGoogle Scholar
• Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol. 2021;1–10. doi:10.1080/08830185.2021.1939696.
   PubMed Web of Science ®Google Scholar
• Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, Salmon D, Yu H. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19:173. doi:10.1186/s12916-021-02059-5.
   PubMed Web of Science ®Google Scholar
• COVID C, Team R. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. Morb Mortal Wkly Rep. 2021;70;46. doi:10.1001/jama.2021.0600.
   PubMed Web of Science ®Google Scholar
• Myocarditis and pericarditis after mRNA COVID-19 vaccination. [ accessed 2021 Sep 1]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html .
   Google Scholar
• Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J, Weintraub E, Shimabukuro T. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on immunization practices—United States, June 2021. Morb Mortal Wkly Rep. 2021;70:977. doi:10.15585/mmwr.mm7027e2external.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;1:11. doi:10.1038/s41577-021-00592-1.
   Google Scholar
• Vaxzevria (previously COVID-19 vaccine AstraZeneca): risk of thrombocytopenia and coagulation disorders. [ accessed 2021 Sep 10]. https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca-risk-thrombocytopenia-coagulation-disorders#documents-section .
   Google Scholar
• Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. [ accessed 2021 Sep 7]. https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine .
   Google Scholar
• MacIntyre CR, Veness B, Berger D, Hamad N, Bari N. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia. Vaccine. 2021;39:4784–87. doi:10.1016/j.vaccine.2021.07.013.
   PubMed Web of Science ®Google Scholar
• Alam W. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review of the potential mechanisms and proposed management. Sci Prog. 2021;104:368504211025927. doi:10.1177/00368504211025927.
   PubMed Web of Science ®Google Scholar
• Selected adverse events reported after COVID-19 vaccination. [ accessed 2021 Sep 7]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html .
   Google Scholar
• Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28:626–39. doi:10.1038/s41418-020-00720-9.
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccines may protect many, but not all, people with suppressed immune systems. [ accessed 2021 Sep 10]. https://www.science.org/news/2021/04/covid-19-vaccines-may-protect-many-not-all-people-suppressed-immune-systems .
   Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325:1784–86. doi:10.1001/jama.2021.4385.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–06. doi:10.1001/jama.2021.7489.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Radbel J, Narayanan N, Bhatt PJ. Use of Tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest. 2020;158(1):e15–e9. doi:10.1016/j.chest.2020.04.024.
   PubMed Web of Science ®Google Scholar
• Krause PR, Gruber MF. Emergency use authorization of covid vaccines - safety and efficacy follow-up considerations. N Engl J Med. 2020;383:e107. doi:10.1056/NEJMp2031373.
   PubMed Web of Science ®Google Scholar
• Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: what have we learned so far and what remains to be done? Health Policy (New York). 2021;125:553–67. doi:10.1016/j.healthpol.2021.03.013.
   PubMed Web of Science ®Google Scholar
• Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354.
   PubMed Web of Science ®Google Scholar
• Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med. 2021;27:1338–39. doi:10.1038/s41591-021-01459-7.
   PubMed Web of Science ®Google Scholar
• Vaccine hesitancy: what it means and what we need to know in order to tackle it. [ accessed 2021 Sep]. https://www.who.int/immunization/research/forums_and_initiatives/1_RButler_VH_Threat_Child_Health_gvirf16.pdf .
   Google Scholar
• Eccleston-Turner M, Upton H. International collaboration to ensure equitable access to vaccines for COVID-19: the ACT-accelerator and the COVAX facility. Milbank Q. 2021;99:426–49. doi:10.1111/1468-0009.12503.
   PubMed Web of Science ®Google Scholar
• Access and allocation: how will there be fair and equitable allocation of limited supplies? [ accessed 2021 Sep 14]. https://www.who.int/news-room/feature-stories/detail/access-and-allocation-how-will-there-be-fair-and-equitable-allocation-of-limited-supplies .
   Google Scholar
• Andreakos E, Tsiodras S. COVID-19: lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 2020;12:e12465. doi:10.15252/emmm.202012465.
   PubMed Web of Science ®Google Scholar
• Vanden Eynde JJ. COVID-19: a brief overview of the discovery clinical trial. Pharmaceuticals (Basel). 2020;13:65. doi:10.3390/ph13040065.
   PubMedGoogle Scholar
• Bollyky TJ, Gostin LO, Hamburg MA. The equitable distribution of COVID-19 therapeutics and vaccines. JAMA. 2020;323:2462–63. doi:10.1001/jama.2020.6641.
   PubMed Web of Science ®Google Scholar
• Krishtel P, Malpani R. Suspend intellectual property rights for covid-19 vaccines. Br Med J. 2021;373:n1344. doi:10.1136/bmj.n1344.
   PubMed Web of Science ®Google Scholar
• Zarocostas J. What next for a COVID-19 intellectual property waiver? Lancet. 2021;397:1871–72. doi:10.1016/s0140-6736(21)01151-x.
   PubMed Web of Science ®Google Scholar
• Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639–44. doi:10.1038/s41586-021-03207-w.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371. doi:10.1126/science.abf4063.
   Web of Science ®Google Scholar
• Marklund E, Leach S, Axelsson H, Nystrom K, Norder H, Bemark M, Angeletti D, Lundgren A, Nilsson S, Andersson L-M, et al. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020;15(10):e0241104. doi:10.1371/journal.pone.0241104.
   PubMed Web of Science ®Google Scholar
• Callaway E. Had COVID? You’ll probably make antibodies for a lifetime. Nature. 2021. doi:10.1038/d41586-021-01442-9.
   Google Scholar
• Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham MS, Klaser K, Modat M, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021;00460–6. doi:10.1016/S1473-3099(21.
   Web of Science ®Google Scholar
• Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021. doi:10.1093/cid/ciab381.
   Web of Science ®Google Scholar
• Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, Sarkar R, Chen W, Cutler M, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466–68. doi:10.1056/NEJMc2102017.
   PubMed Web of Science ®Google Scholar
• Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv. 2021. doi:10.1101/2021.01.25.427948.
   Google Scholar
• Ebanks D, Faustini S, Shields A, Parry H, Moss P, Plant T, Richter A, Drayson M. Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays. J Infect. 2021; 83(4):e18–20. S0163-4453(21)00363-7. doi:10.1016/j.jinf.2021.07.020.
   PubMed Web of Science ®Google Scholar
• UK to support rest of the world to find COVID-19 virus variants. [ accessed 2021 Sep 16]. https://www.gov.uk/government/news/uk-to-support-rest-of-the-world-to-find-covid-19-virus-variants .
   Google Scholar
• Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants—clinical, public health, and vaccine implications. N Engl J Med. 2021;384:1866–68. doi:10.1056/NEJMc2100362.
   PubMed Web of Science ®Google Scholar
• Coronavirus (COVID-19) update: FDA issues policies to guide medical product developers addressing virus variants. [ accessed 2021 Sep 16]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus.
   Google Scholar